ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00158548
Recruitment Status :
First Posted : September 12, 2005
Last Update Posted : January 12, 2017
London School of Hygiene and Tropical Medicine
World Health Organization
United Nations High Commissioner for Refugees
Pakistan Directorate of Malaria Control
Information provided by (Responsible Party):
Brian Greenwood, London School of Hygiene and Tropical Medicine
Chloroquine resistant falciparum malaria in Pakistan is prevalent in every malarious area examined. Resistance to the favoured second-line treatment, sulphadoxine-pyrimethamine S/P is rising fast. To avert a repetition of the resistance catastrophe that occurred in SE Asia it is critical to preserve the effective life of SP by using it in combination with artesunate. Efficacy of ACT with artesunate in combination with chloroquine, SP or amodiaquine for treatment of malaria (falciparum or vivax) will be examined in malaria patients in Pakistan.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.